The 36-month beta value for CTXR is at 1.45. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CTXR is 146.79M, and currently, shorts hold a 8.30% of that float. The average trading volume for CTXR on April 02, 2024 was 677.17K shares.
CTXR) stock’s latest price update
Citius Pharmaceuticals Inc (NASDAQ: CTXR) has experienced a rise in its stock price by 14.79 compared to its previous closing price of 0.90. However, the company has seen a gain of 30.68% in its stock price over the last five trading days. PRNewsWire reported 2024-02-23 that CRANFORD, N.J., Feb. 23, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two upcoming investor conferences.
CTXR’s Market Performance
Citius Pharmaceuticals Inc (CTXR) has experienced a 30.68% rise in stock performance for the past week, with a 34.06% rise in the past month, and a 33.47% rise in the past quarter. The volatility ratio for the week is 10.87%, and the volatility levels for the past 30 days are at 7.99% for CTXR. The simple moving average for the past 20 days is 36.02% for CTXR’s stock, with a 22.20% simple moving average for the past 200 days.
Analysts’ Opinion of CTXR
Many brokerage firms have already submitted their reports for CTXR stocks, with Maxim Group repeating the rating for CTXR by listing it as a “Buy.” The predicted price for CTXR in the upcoming period, according to Maxim Group is $4 based on the research report published on November 30, 2021 of the previous year 2021.
CTXR Trading at 42.44% from the 50-Day Moving Average
After a stumble in the market that brought CTXR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.77% of loss for the given period.
Volatility was left at 7.99%, however, over the last 30 days, the volatility rate increased by 10.87%, as shares surge +32.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +37.33% upper at present.
During the last 5 trading sessions, CTXR rose by +30.68%, which changed the moving average for the period of 200-days by -18.25% in comparison to the 20-day moving average, which settled at $0.7698. In addition, Citius Pharmaceuticals Inc saw 36.15% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CTXR
The total capital return value is set at -0.42. Equity return is now at value -41.24, with -36.52 for asset returns.
Based on Citius Pharmaceuticals Inc (CTXR), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -70.87. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -10.22.
Currently, EBITDA for the company is -36.54 million with net debt to EBITDA at 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.06.
Conclusion
In conclusion, Citius Pharmaceuticals Inc (CTXR) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
